Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience.

ABSTRACT:

Background

Serotonin syndrome (SS) symptoms overlap with adverse events associated with lasmiditan, a 5-HT (serotonin)_1F receptor agonist for acute treatment of migraine. Because SS symptoms are heterogeneous, diagnosis can be challenging, and potential cases observed with lasmiditan treatment led to questions about SS pathophysiology. Here, we provide an overview of the potential risk of SS based on experience with lasmiditan.

Methods

Results of eight phase 2 and phase 3 lasmiditan trials (n = 5,916) and a controlled intravenous trial of lasmiditan (n = 88) were analyzed for symptomatology consistent with SS. Post-marketing surveillance data from lasmiditan's US launch date (January 2020) until data cut-off (April 2021) were also examined. Establish

SUBMITTER: Blumenfeld A 

PROVIDER: S-EPMC10641788 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature